Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

Pfizer PFE is facing one of the steepest patent cliffs in the large-cap pharma space. The company expects a significant ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.

AstraZeneca AZN recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. The announcement comes just days after Pfizer PFE signed a similar deal ...

Good news for Pfizer could be good news for AstraZeneca, for two reasons. First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer's could be on the ...

When seven biopharma executives were asked by senators in February whether they had intentionally blocked generic competition, all of them said no. But several of the companies’ products were included ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. After gaining accelerated approval in the indication in 2017, the company grudgingly clawed back ...

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...